Symposium 35 : simplebooklet.com

12:00-12:05 pm12:05-12:30 pm12:30-1:00 pm1:00-2:00 pmWELCOME AND INTRODUCTIONSQ&A WITH DISCUSSANTSOVERVIEW OF BOOSTERSKathleen M. Neuzil, MD, MPH, FIDSAMyron M. Levine Professor in Vaccinology Director, Center for Vaccine Development and Global HealthUniversity of Maryland School of MedicineFred Sanfilippo, MD, PhDDirector, Emory-Georgia Tech Healthcare Innovation ProgramProfessor of Pathology & Laboratory Medicine, Emory University School of MedicineProfessor of Health Policy & Management, Rollins School of Public Health PROCESS & RATIONALE FOR CDC RECOMMENDATIONSSara E. Oliver, MD, MSPHMedical OfficerDivision of Viral DiseasesLead, ACIP COVID-19 Vaccines Work GroupCenters for Disease Control and PreventionRafi Ahmed, PhDDirector, Emory Vaccine CenterProfessor, Department of Microbiology and ImmunologyEmory University School of MedicineEminent Scholar, Georgia Research AllianceWalter A. Orenstein, MDAssociate Director, Emory Vaccine CenterProfessor, Department of Medicine, Division of Infectious DiseasesEmory University School of MedicineDirector, Emory Center of Research for Influenza Research and Response (Emory CEIRR)Carlos Del Rio, MDDistinguished Professor of MedicineEmory University School of MedicineExecutive Associate Dean Emory at GradyProgramKEYNOTE SPEAKERS

Page 3

Kathleen M. Neuzil, MD, MPH, FIDSACenter for Vaccine Development and Global HealthUniversity of MarylandKathleen Neuzil is the Myron M. Levine Professorin Vaccinology, Professor of Medicine andPediatrics, and the Director of the Center forVaccine Development and Global Health at theUniversity of Maryland School of Medicine. She isan internationally recognized research scientistand advocate in the field of vaccinology.Throughout her career, Dr. Neuzil has conductedclinical and epidemiologic studies on vaccine-preventable diseases, yielding high-profilepublications that inform policy decisions and publichealth actions. Dr. Neuzil’s work has spanneddozens of low-resource countries with multiplevaccines, including influenza, rotavirus, humanpapillomavirus, Japanese encephalitis, typhoidconjugate vaccines, and most recently, COVID-19vaccines. Dr. Neuzil is central to the domestic and globalresponse to COVID. As a co-PI of the NIH-fundedLeadership Group for the Vaccine and TreatmentEvaluation Unit network, Dr. Neuzil is part of thestrategic team evaluating COVID vaccines andtherapeutics in the US and was part of the studyteam who designed the first COVID-19 clinicalvaccine trial in the US. The CVD is likewiseparticipating in COVID treatment and post-exposure prophylaxis trials. Dr. Neuzil also directs TyVAC, the Typhoid VaccineAcceleration Consortium, with the goal toaccelerate the introduction of typhoid conjugatevaccines into low-resource countries. She hasmore than 230 scientific publications on vaccinesand infectious diseases. Dr. Neuzil's research capabilities are complimented by 20 years ofinvolvement in domestic and internationalpolicy, including past membership on the USCenters for Disease Control and Prevention’sAdvisory Committee on ImmunizationPractices. She is a member of the WorldHealth Organization Strategic Advisory Groupof Experts on Immunization and is a memberof the National Academy of Medicine.

Page 4

Sara E. Oliver, MDACIP COVID-19 Vaccines Work GroupCenters for Disease Control and Prevention (CDC)Dr. Sara Oliver currently serves as theLead for the COVID-19 vaccines ACIP WorkGroup and a Medical Officer in the Divisionof Viral Diseases, National Center forImmunizations and Respiratory Diseases(NCIRD). She is board certified in Pediatricsand Pediatric Infectious Disease and has aMasters of Science in Public Health. She obtained her medical degree from theUniversity of Alabama at BirminghamSchool of Medicine, completed a Pediatricsresidency at Cincinnati Children’s HospitalMedical Center, a Pediatric InfectiousDisease Fellowship at the Children’sHospital of Alabama and at the Universityof Alabama at Birmingham. Dr. Oliver came to the CDC in 2015 as anEpidemic Intelligence Service Officer, withthe Division of STD Prevention andDivision of Viral Diseases, working on HPVand other infections. After EIS, she joinedthe Division of Bacterial Diseases as amedical officer in the Meningitis andVaccine Preventable Diseases Branch.She’s been working on the COVID-19pandemic since January of 2020 and hasofficially transitioned to work on COVID-19vaccine policy full time within the Divisionof Viral Diseases at CDC.

Page 5

Rafi Ahmed, PhD Emory Vaccine CenterEmory University School of MedicineDr. Rafi Ahmed, a member of the NationalAcademy of Science, is a world-renownedimmunologist whose work during the pastdecade has been highly influential in shapingour current understanding of memory T celldifferentiation and anti-viral T and B cellimmunity. The long-term goal of Dr. Ahmed'sresearch is to understand the mechanismsof B and T cell immunological memory andto use this information to develop newvaccines for the prevention and treatment ofdisease. The Ahmed laboratory uses highlysophisticated cellular and moleculartechniques to study antigen-specificimmunological memory in murine, primate,and human systems. A major area of focus isidentifying cellular molecules that regulatethe generation and maintenance of CD8 andCD4 T cell and humoral immunity. One suchmolecule is mTOR that was recentlyidentified as a major regulator of memoryCD8 T cell differentiation. Another area of focus is developingstrategies to restore function in virus-specific T cells during a chronic viralinfection such as HIV or Varicella-zoster virus(VZV). A key breakthrough by the Ahmedlaboratory several years ago demonstratedthe striking differences in memory CD8 T celldifferentiation during acute versus chronicviral infection resulting in the identificationof the inhibitory receptor, PD-1, as a majormediator of T cell dysfunction during chronicinfection.. Another approach of the Ahmedlaboratory is understanding humoralmemory development andmaintenance. They have co-developed a novel method for rapidlygenerating human monoclonalantibodies after vaccination and haveshown that broadly cross-reactiveantibodies that recognize multipleinfluenza viruses can be generatedafter influenza vaccination inhumans. These studies and thosecurrently on going which includeunderstanding the mechanisms thatregulate the development ofneutralizing antibody give rise to thepossibility that a universal influenzavaccine could be developed in thenear future.

Page 6

Walter A. Orenstein, MD, is a Professor of Medicine,Epidemiology, Global Health, and Pediatrics atEmory University; as well as the Associate Directorof the Emory Vaccine Center and Director, EmoryVaccine Policy and Development. From 2008through 2011, Dr. Orenstein was Deputy Directorfor Immunization Programs at the Bill & MelindaGates Foundation. His primary focus at thefoundation had been on polio eradication, measlescontrol, and improving routine immunizationprograms. Prior to 2004, Dr. Orenstein worked for26 years in the Immunization Program at theCenters for Disease Control and Prevention. From1988-2004, he was the Director of the UnitedStates Immunization Program. He is a formerAssistant Surgeon General of the USPHS. Dr.Orenstein successfully developed, promoted,facilitated and expanded new vaccination strategiesto enhance disease prevention. Dr. Orenstein has authored and co-authorednumerous books, journals and reviews. Dr.Orenstein co-edited Plotkin’s Vaccines, 7th editionin 2018 – the leading textbook in the field. He is apast Chair of the WHO’s Poliomyelitis TechnicalConsultative Group. He served as the Chair of theNational Vaccine Advisory Committee (NVAC) from2012 to 2016. He is also currently a member of theWHO’s Strategic Advisory Group of Experts (SAGE)on Immunization Polio as well as Measles andRubella Working Groups. He is currently the Chairof WHO’s Immunization and Vaccines RelatedImplementation Research Advisory Committee(IVIR-AC). Between July 1, 2016 and June 30, 2018,Dr. Orenstein was the President of the NationalFoundation for Infectious Diseases (NFID). Dr. Orenstein’s research focus has been onassessment of vaccine effectiveness inobservational studies, methods to overcomevaccine hesitancy, ways to enhance uptake of Walter A. Orenstein, MDEmory Vaccine CenterEmory University School of Medicinerecommended vaccines, and ways tofacilitate polio eradication and sustainthat eradication. In addition, Dr.Orenstein is the Principal Investigator forthe Center of Excellence for InfluenzaResearch and Surveillance (Emory-UGACEIRS), one of five national Centers ofExcellence for Influenza Research andSurveillance (CEIRS) funded by NIH/NIAID.with a focus on better understandingpathogenesis, immune responses tovaccines and infection, and viralsurveillance in animal populations. TheCenter's structure is comprised ofresearch (human and animal) projects,pilot projects (novel ideas), datamanagement, animal surveillance(domestic and foreign), and CEIRS Cross-Network projects

Page 7

Carlos del Rio, MD is a Distinguished Professorof Medicine in the Division of InfectiousDiseases at Emory University School ofMedicine. He is also Executive Associate Deanfor Emory at Grady, PI and co-Director of theEmory Center for AIDS Research (CFAR) and co-PI of the Emory-CDC HIV Clinical Trials Unit andthe Emory Vaccine Treatment and EvaluationUnit. Dr. del Rio is a native of Mexico where heattended medical school at Universidad La Salle,graduating in 1983. He did his Internal Medicineand Infectious Diseases residencies at EmoryUniversity. In 1989 he returned to Mexico wherehe was Executive Director of the National AIDSCouncil of Mexico (CONASIDA, the Federalagency of the Mexican Government responsiblefor AIDS Policy throughout Mexico), from 1992through 1996. In November of 1996 hereturned to Emory where he has been involvedin teaching and research. Dr. del Rio was Chiefof the Emory Medical Service at Grady MemorialHospital from 2001-2009 and Chair of theHubert Department of Global Health from2009-2019. His research interests include theepidemiology of opportunistic infections in HIVand other immune deficiencies theepidemiology and transmission dynamics of HIVand other sexually transmitted diseases andissues related to early diagnosis of HIV, accessto care and compliance with antiretrovirals. Dr. del Rio is a Member of the Scientific AdvisoryCommittee of the Latin-American AIDS Initiative(SIDALAC), Member of the Monitoring of theAIDS Pandemic (MAP) Network, Member of the Carlos Del Rio, MDEmory University School of MedicineEmory at GradyBoard of the IAS-USA, member of theUNAIDS Scientific Technical AdvisoryCommittee and Chair of the PEPFARScientific Advisory Board. He isAssociate Editor for Clinical InfectiousDiseases and Senior Editor for HIV forNEJM Journal Watch InfectiousDiseases as well as an editorial boardmember of Global Public Health,Journal of AIDS and Women, Children &HIV. He has co-authored 5 books, 30book chapters, and over 450 scientificpapers.

Page 8

Fred Sanfilippo, MD, PhD directs the Emory-Georgia Tech Healthcare Innovation Program,which has a mission to accelerate innovationin healthcare delivery science research,education, and service. He also serves asProfessor of Pathology and LaboratoryMedicine and Health Policy and Managementat Emory, and former Medical Director of theMarcus Foundation. For over 30 years he has been an academicleader at Duke, Johns Hopkins, Ohio State andEmory; serving as a division chief, departmentchair, program/center director, dean, medicalcenter CEO, university senior/executive VP,health system board chair and academichealth center CEO. During that time he hasled organizational and cultural changesyielding improved academic, clinical, andfinancial performance at each institution. Healso led the creation of the US ScientificRegistry of Transplant Recipients; JohnsHopkins Medical Labs; a personalized healthplan (YP4H) at OSU; and novel departmentsand centers in areas ranging from BiomedicalInformatics to Personalized Health andIntegrative Medicine. Sanfilippo received his BA and MS in physicsfrom the University of Pennsylvania, and hisMD and PhD in immunology from Duke,where he also did his residency training,receiving board certification in Anatomic &Clinical Pathology, and Immunopathology. Fred Sanfilippo, MD, PhDEmory-Georgia Tech Healthcare Innovation ProgramEmory UniversityHe has mentored more than 30 graduate student and fellows, servedon 13 editorial boards, publishedover 250 articles, received threepatents, and been awarded over $30million in sponsored research. He hasbeen board chair of five non-profits,and president of seven academic andprofessional organizations includingthe American Society of InvestigativePathology and the American Societyof Transplantation.

Symposium 35

Page 1